AstraZeneca Pharma India has received permission to import and distribute Olaparib Tablets (100 mg & 150 mg) for the maintenance treatment of advanced or recurrent endometrial cancer after first-line treatment. This approval enables the launch of the product in India, pending any further regulatory approvals.